Kate Therapeutics

Kate Therapeutics is developing adeno-associated virus (AAV)-based gene therapies to treat muscle and heart diseases. The current limitations with gene therapies include tissue-specific delivery, liver detargeting and gene regulation. Kate is applying their novel technology platforms to improve the safety and efficacy of AAV gene therapy: this includes their novel capsids that provide superior muscle and heart transduction compared to naturally occurring serotypes that are currently used in clinical trials. With these advances, Kate is establishing a pipeline of muscle and cardiac disease indications that can be addressed with their capsid and cargo technologies.

Jobs: